ADAPY

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-36.6K ExitQ4 2025 $37k -- $0.028
Jim SimonsRenaissance Technologies $-527.0K ExitQ4 2025 $527k -- $0.028
Jim SimonsRenaissance Technologies $75.7K AddQ3 2025 $76k -- $0.028
Ken GriffinCitadel Advisors $-15.0K ExitQ2 2025 $15k -- $0.028
Jim SimonsRenaissance Technologies $94.0K AddQ2 2025 $94k -- $0.028
Ken GriffinCitadel Advisors $-96.0K TrimQ1 2025 $96k -- $0.028

Insider Trades

Name	Value	Action	Price	Last Price
Wood GavinChief Financial Officer $95096k shares SellSep 2, 2025 $0.0099 $0.028
Bertrand William C JRChief Operating Officer $2.1k207k shares SellAug 28, 2025 $0.0101 $0.028
Behbahani AliDirector $176k14.7M shares SellAug 18, 2025 $0.012 $0.028
Behbahani AliDirector $53k4.8M shares SellAug 15, 2025 $0.011 $0.028
EcoR1 Capital, LLC10 Percent Owner $3M27.4M shares SellJul 30, 2025 $0.1021 $0.028
EcoR1 Capital, LLC10 Percent Owner $4M33.9M shares SellJul 28, 2025 $0.1125 $0.028

Trade ADAPY

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.

CEO: Christopher James Hill
IPO Date: May 6, 2015

Market Data

Open: $0.04
High: $0.04
Low: $0.031
Volume: 518.4K
Avg Volume: 440K
52W High: $0.358
52W Low: $0.001

Valuation

Market Cap: $10.6M
Enterprise Value: $33.2M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$75.9M
Revenue: $178M
Net Income: -$70.8M
Cash: $91.1M
Debt: $74.2M

Events

EarningsAug 12

EPS est. -0.02